Somnomed (SOM.AX) Stock Price

Somnomed Price

ASX·CLOSED
0.41AUD-0.0050 (-1.23 %)
Market closed

Revenue has compounded at 24.3% per year over the past 19 years to 111.52 M AUD. Earnings per share have declined at 26.5% per year over the last 6 years. Somnomed's net margin stands at -3.1%, down from -1.9% several years earlier. Analysts set a median price target of 1.01 AUD, implying 150.6% above the current price. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.

Somnomed stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Somnomed over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Somnomed stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Somnomed's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Somnomed Stock Price History
DateSomnomed Price
8/11/20260.41 AUD
8/10/20260.41 AUD
8/7/20260.42 AUD
8/6/20260.42 AUD
8/5/20260.42 AUD
8/4/20260.42 AUD
8/3/20260.44 AUD
7/31/20260.45 AUD
7/30/20260.47 AUD
7/29/20260.47 AUD
7/28/20260.47 AUD
7/27/20260.47 AUD
7/24/20260.45 AUD
7/23/20260.47 AUD
7/22/20260.47 AUD
7/21/20260.42 AUD
7/20/20260.45 AUD
7/17/20260.46 AUD
7/16/20260.48 AUD
7/15/20260.46 AUD
7/14/20260.48 AUD
7/13/20260.50 AUD
7/10/20260.49 AUD
7/9/20260.52 AUD
7/8/20260.55 AUD
7/7/20260.54 AUD
7/6/20260.54 AUD
7/3/20260.50 AUD
7/2/20260.50 AUD
7/1/20260.52 AUD
6/30/20260.53 AUD
6/29/20260.54 AUD
6/26/20260.54 AUD
6/25/20260.54 AUD
6/24/20260.54 AUD
6/23/20260.54 AUD
6/22/20260.54 AUD
6/19/20260.56 AUD
6/18/20260.55 AUD
6/17/20260.55 AUD
6/16/20260.55 AUD
6/15/20260.58 AUD
6/12/20260.52 AUD
6/11/20260.58 AUD
6/10/20260.58 AUD
6/9/20260.59 AUD
6/5/20260.60 AUD
6/4/20260.60 AUD
6/3/20260.60 AUD
6/2/20260.60 AUD
6/1/20260.57 AUD
5/29/20260.57 AUD
5/28/20260.57 AUD
5/27/20260.55 AUD
5/26/20260.55 AUD
5/25/20260.55 AUD
5/22/20260.55 AUD
5/21/20260.55 AUD
5/20/20260.56 AUD
5/19/20260.56 AUD
5/18/20260.55 AUD
5/15/20260.57 AUD
5/14/20260.57 AUD
5/13/20260.57 AUD
5/12/20260.60 AUD
5/11/20260.60 AUD
5/8/20260.60 AUD
5/7/20260.60 AUD
5/6/20260.60 AUD
5/5/20260.61 AUD
5/4/20260.61 AUD
5/1/20260.57 AUD
4/30/20260.56 AUD
4/29/20260.57 AUD
4/28/20260.57 AUD
4/27/20260.62 AUD
4/24/20260.63 AUD
4/23/20260.57 AUD
4/22/20260.53 AUD
4/21/20260.57 AUD
4/20/20260.58 AUD
4/17/20260.60 AUD
4/16/20260.58 AUD
4/15/20260.58 AUD
4/14/20260.58 AUD
4/13/20260.57 AUD
4/10/20260.56 AUD
4/9/20260.56 AUD
4/8/20260.60 AUD
4/7/20260.62 AUD
4/2/20260.59 AUD
4/1/20260.62 AUD
3/31/20260.65 AUD
3/30/20260.64 AUD
3/27/20260.64 AUD
3/26/20260.65 AUD
3/25/20260.65 AUD
3/24/20260.65 AUD
3/23/20260.63 AUD
3/20/20260.64 AUD
3/19/20260.67 AUD
3/18/20260.67 AUD
3/17/20260.64 AUD
3/16/20260.64 AUD
3/13/20260.66 AUD
3/12/20260.70 AUD
3/11/20260.69 AUD
3/10/20260.65 AUD
3/9/20260.67 AUD
3/6/20260.68 AUD
3/5/20260.70 AUD
2/25/20260.66 AUD
2/24/20260.69 AUD
2/23/20260.71 AUD
2/20/20260.67 AUD
2/19/20260.67 AUD
2/17/20260.71 AUD
2/16/20260.70 AUD
2/13/20260.70 AUD
2/12/20260.73 AUD
2/11/20260.70 AUD
2/10/20260.70 AUD
2/9/20260.63 AUD
2/6/20260.62 AUD
2/5/20260.64 AUD
2/4/20260.66 AUD
2/3/20260.65 AUD
2/2/20260.64 AUD
1/30/20260.67 AUD
1/29/20260.68 AUD
1/28/20260.66 AUD
1/27/20260.64 AUD
1/23/20260.65 AUD
1/22/20260.66 AUD
1/21/20260.66 AUD
1/20/20260.68 AUD
1/19/20260.67 AUD
1/16/20260.70 AUD
1/15/20260.71 AUD
1/14/20260.71 AUD
1/13/20260.70 AUD
1/12/20260.71 AUD
1/9/20260.72 AUD
1/8/20260.74 AUD
1/7/20260.75 AUD
1/6/20260.78 AUD
1/5/20260.76 AUD
1/2/20260.77 AUD
12/30/20250.75 AUD
12/29/20250.75 AUD
12/24/20250.76 AUD
12/23/20250.77 AUD
12/19/20250.80 AUD
12/18/20250.76 AUD
12/17/20250.76 AUD
12/16/20250.77 AUD
12/15/20250.76 AUD
12/12/20250.76 AUD
12/11/20250.78 AUD
12/10/20250.79 AUD
12/9/20250.80 AUD
12/8/20250.78 AUD
12/5/20250.79 AUD
12/4/20250.80 AUD
12/3/20250.80 AUD
12/2/20250.81 AUD
12/1/20250.79 AUD
11/28/20250.80 AUD
11/27/20250.80 AUD
11/26/20250.81 AUD
11/25/20250.79 AUD
11/24/20250.77 AUD
11/21/20250.79 AUD
11/20/20250.79 AUD
11/19/20250.78 AUD
11/18/20250.78 AUD
11/17/20250.78 AUD
11/14/20250.78 AUD
11/13/20250.78 AUD
11/12/20250.78 AUD
11/11/20250.77 AUD
11/10/20250.77 AUD
11/7/20250.77 AUD
11/6/20250.77 AUD
11/5/20250.80 AUD
11/4/20250.81 AUD
11/3/20250.84 AUD
10/31/20250.85 AUD
10/30/20250.88 AUD
10/29/20250.86 AUD
10/28/20250.86 AUD
10/27/20250.85 AUD
10/24/20250.85 AUD
10/23/20250.87 AUD
10/22/20250.85 AUD
10/21/20250.88 AUD
10/20/20250.87 AUD
10/17/20250.83 AUD
10/16/20250.86 AUD
10/15/20250.87 AUD
10/14/20250.88 AUD
10/13/20250.87 AUD
10/10/20250.85 AUD
10/9/20250.87 AUD
10/8/20250.83 AUD
10/7/20250.83 AUD
10/6/20250.84 AUD
10/3/20250.82 AUD
10/2/20250.79 AUD
10/1/20250.75 AUD
9/30/20250.78 AUD
9/29/20250.76 AUD
9/26/20250.75 AUD
9/25/20250.77 AUD
9/24/20250.74 AUD
9/23/20250.73 AUD
9/22/20250.74 AUD
9/19/20250.73 AUD
9/18/20250.75 AUD
9/17/20250.74 AUD
9/16/20250.74 AUD
9/15/20250.75 AUD
9/12/20250.74 AUD
9/11/20250.74 AUD
9/10/20250.75 AUD
9/9/20250.75 AUD
9/8/20250.72 AUD
9/5/20250.71 AUD
9/4/20250.74 AUD
9/3/20250.74 AUD
9/2/20250.72 AUD
9/1/20250.78 AUD
8/29/20250.80 AUD
8/28/20250.79 AUD
8/27/20250.78 AUD
8/26/20250.74 AUD
8/25/20250.71 AUD
8/22/20250.73 AUD
8/21/20250.70 AUD
8/20/20250.70 AUD
8/19/20250.70 AUD
8/18/20250.73 AUD
8/15/20250.76 AUD
8/14/20250.75 AUD
Access this data via the Eulerpool API
Get Free API Key

Somnomed Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
72.58 M AUD
-4.13 M AUD
-4.44 M AUD
Jan 1, 2023
83.62 M AUD
-4.07 M AUD
-8.00 M AUD
Jan 1, 2024
91.68 M AUD
-8.30 M AUD
-12.24 M AUD
Jan 1, 2025
111.52 M AUD
-288,400.00 AUD
-3.46 M AUD
Jan 1, 2026 (e)
121.67 M AUD
-4.75 M AUD
2.14 M AUD
Jan 1, 2027 (e)
131.72 M AUD
-5.14 M AUD
4.88 M AUD
Jan 1, 2028 (e)
143.41 M AUD
-5.60 M AUD
6.99 M AUD
Jan 1, 2029 (e)
142.40 M AUD
-5.56 M AUD
0.00 AUD

Somnomed Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 12, 2026, 7:44 PM
 
REVENUEM AUD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM AUD
EBITM AUD
EBIT MARGIN%
NET INCOMEM AUD
NET INCOME GROWTH%
SHARESM
2014201520162017201820192020202120222023202420252026e2027e2028e2029e
30.0034.0044.0049.0063.0058.0057.0062.0072.0083.0091.00111.00121.00131.00143.00142.00
66.6713.3329.4111.3628.57-7.94-1.728.7716.1315.289.6421.989.018.269.16-0.70
53.3355.8856.8257.1460.3258.6257.8959.6861.1161.4560.4459.4659.4659.4659.4659.46
16.0019.0025.0028.0038.0034.0033.0037.0044.0051.0055.0066.0071.9577.8985.0384.43
–––-3.00-8.00–––-4.00-4.00-8.00–-4.00-5.00-5.00-5.00
–––-6.12-12.70–––-5.56-4.82-8.79–-3.31-3.82-3.50-3.52
–––-3.00-8.00-16.00-1.00-1.00-4.00-7.00-12.00-3.002.004.006.00–
––––166.67100.00-93.75–300.0075.0071.43-75.00-166.67100.0050.00–
70.2179.2682.1884.5087.5391.4785.31105.97106.15106.15120.73211.91211.91211.91211.91211.91
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Somnomed generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Somnomed retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Somnomed's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Somnomed has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Somnomed's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Somnomed stock margins

The Somnomed margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Somnomed. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Somnomed.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
60.19 %
-1.36 %
-1.90 %
Jan 1, 2022
61.01 %
-5.69 %
-6.11 %
Jan 1, 2023
62.10 %
-4.86 %
-9.57 %
Jan 1, 2024
60.17 %
-9.05 %
-13.35 %
Jan 1, 2025
59.86 %
-0.26 %
-3.10 %
Jan 1, 2026 (e)
59.86 %
-3.91 %
1.76 %
Jan 1, 2027 (e)
59.86 %
-3.91 %
3.71 %
Jan 1, 2028 (e)
59.86 %
-3.91 %
4.87 %

Somnomed Stock Revenue, EBIT, Earnings per Share

The Somnomed earnings per share therefore indicates how much revenue Somnomed has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.59 AUD
-0.01 AUD
-0.01 AUD
Jan 1, 2022
0.68 AUD
-0.04 AUD
-0.04 AUD
Jan 1, 2023
0.79 AUD
-0.04 AUD
-0.08 AUD
Jan 1, 2024
0.76 AUD
-0.07 AUD
-0.10 AUD
Jan 1, 2025
0.53 AUD
-0.00 AUD
-0.02 AUD
Jan 1, 2026 (e)
0.57 AUD
-0.02 AUD
0.01 AUD
Jan 1, 2027 (e)
0.62 AUD
-0.02 AUD
0.02 AUD
Jan 1, 2028 (e)
0.68 AUD
-0.03 AUD
0.03 AUD

Somnomed business model & stock analysis

SomnoMed Ltd is a leading medical technology company based in Sydney, Australia. It was founded in 2004 and specializes in the development and distribution of medical devices for the treatment of sleep apnea and bruxism.

Somnomed SWOT Analysis

Strengths

Somnomed Ltd has several strengths that give it a competitive advantage in the market. These strengths include:

  • Strong brand reputation and recognition in the industry.
  • High-quality products and advanced technology.
  • Wide distribution network and global presence.
  • Strong relationships with key stakeholders, including dentists and sleep physicians.
  • Established customer base and loyal clientele.

Weaknesses

Despite its strengths, Somnomed Ltd also faces certain weaknesses that could hinder its growth and performance. These weaknesses include:

  • Relatively higher product pricing compared to competitors.
  • Dependency on a limited number of suppliers for essential raw materials.
  • Limited product portfolio offering, focusing primarily on oral devices.
  • Possibility of product recalls impacting company reputation.
  • Higher costs associated with research and development.

Opportunities

Somnomed Ltd can capitalize on various opportunities in the market to further expand its business. These opportunities include:

  • Increasing prevalence of sleep disorders globally, providing a growing market demand.
  • Expansion into emerging markets with a rising awareness of sleep disorders.
  • Development of innovative products to cater to specific patient needs.
  • Collaboration with healthcare providers to promote the importance of sleep disorder treatment.
  • Integration of digital technologies to enhance customer experience and provide remote monitoring.

Threats

However, Somnomed Ltd also faces threats that may pose challenges to its growth and sustainability. These threats include:

  • Intense competition from existing and new market entrants.
  • Stringent regulatory requirements for medical devices and treatments.
  • Economic downturn or fluctuations impacting consumer purchasing power.
  • Emergence of alternative treatment options for sleep disorders.
  • Negative publicity or legal issues related to product safety or efficacy.

Somnomed Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Somnomed historical P/E ratio, EBIT multiple, and P/S ratio

Somnomed annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Somnomed shares outstanding

The number of shares of Somnomed was 211.91 M in 2025. This indicates how many shares Somnomed is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
105.97 M Stocks
Jan 1, 2022
106.15 M Stocks
Jan 1, 2023
106.15 M Stocks
Jan 1, 2024
120.73 M Stocks
Jan 1, 2025
211.91 M Stocks
Jan 1, 2026 (e)
211.91 M Stocks
Jan 1, 2027 (e)
211.91 M Stocks
Jan 1, 2028 (e)
211.91 M Stocks

Somnomed stock splits

In Somnomed's history, there have been no stock splits.

Current Somnomed forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
85.71 % (6)
Hold
14.29 % (1)
Sell
0.00 % (0)
12M Price Target
1.01
Last Price
0.41
Currency
AUD
12M Return Potential
150.59 %
LTM Return
0 %

Somnomed Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
2/20/2024-0.02AUD-44.44 MAUD-2024 Q2
8/7/2023-0.01AUD-46.18 MAUD-2023 Q4
10/27/2022-0.04AUD-40.90 MAUD-2023 Q2
8/22/2022-0.02AUD--AUD-2022 Q4

Somnomed shareholder structure

% Name
1.12895%
Blickstead (Amrita)
Blickstead (Amrita)
0.59649%
Borg (Karen)
Borg (Karen)

Somnomed Beneficial Ownership Filings (SEC 13D/G)

Free Float
77.1%
Float Shares
-
Shares Outstanding
-

Somnomed Executives and Management Board

12 members · avg. age 64 · 25 % women

MC

Mr. Matthew Conlon

Executive Vice President – Marketing and Sales North America

569,191.00 AUD

Management

MH

Mr. Mark Harding

Vice President - Global Marketing

490,938.00 AUD
MK

Mr. Marco Van Kleef

Vice President – Marketing & Sales Europe

320,031.00 AUD
AB

Ms. Amrita Blickstead

Joint Co-Chief Executive Officer, Executive Director · since 2020

90,978.00 AUD
KB

Ms. Karen Borg

Joint Co-Chief Executive Officer, Executive Director · since 2020

90,978.00 AUD
TF

Mr. Terence Flitcroft

Company Secretary · since 1995

35,377.00 AUD
YG

Ms. Ye-fei Guo

Chief Financial Officer

–

Board of Directors

GR

Mr. Guy Russo (64)

Non-Executive Chairman of the Board

184,227.00 AUD
MG

Mr. Michael Gordon

Non-Executive Director

92,113.00 AUD
AP

Mr. Andrew Price

Director

–
BG

Mr. Benjamin Gisz

Non-Executive Director

–

Somnomed Supply Chain

Somnomed Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
2 companies
#NameTrend
1
Australian Ethical Investment
Supplier·Customer·Capital Markets·AU
0.74
0.35
0.53
0.87
0.74
—
2
HSBC Holdings
Supplier·Customer·Banks·GB
-0.45
0.60
0.38
-0.57
-0.66
—

Frequently asked questions about Somnomed

The business model of Somnomed Ltd revolves around the manufacturing and selling of medical devices to treat patients with sleep-related breathing disorders such as obstructive sleep apnea (OSA). Somnomed specializes in creating oral devices known as mandibular advancement splints (MAS) that are worn during sleep to help keep the airway open and improve breathing. These custom-designed devices are crafted using dental impressions and are prescribed by healthcare professionals. Somnomed focuses on delivering innovative and high-quality solutions to help patients improve their quality of sleep and overall well-being.

Somnomed Ltd is primarily active in the medical device industry, specifically focusing on the treatment of sleep-related breathing disorders. With its innovative oral appliance therapy, the company provides effective solutions for patients suffering from conditions such as sleep apnea. As a leader in dental sleep medicine, Somnomed Ltd partners with healthcare professionals worldwide to improve the quality of life for individuals affected by sleep disorders.

The main competitors of Somnomed Ltd in the market include companies such as ResMed Inc., i3DiCAM, and Panthera Dental. These companies compete with Somnomed Ltd in the field of sleep apnea and dental solutions. ResMed Inc. is a leading global provider of medical equipment, focusing on sleep apnea and other respiratory disorders. i3DiCAM specializes in 3D imaging and CAD/CAM solutions for dental applications. Panthera Dental offers innovative dental sleep solutions and services. While Somnomed Ltd holds a strong market position with its range of oral devices and sleep apnea treatments, it faces competition from these established players in the industry.

Somnomed Ltd is a leading company in the dental sleep medicine industry. Established in 2004, it has become a global leader in providing innovative solutions for the treatment of sleep-related breathing disorders such as sleep apnea. With headquarters in Australia, Somnomed has expanded its presence worldwide, offering state-of-the-art oral appliances that improve patients' quality of life. The company has a strong commitment to research and development, continuously striving to deliver advanced technologies and improve treatment outcomes. Through its dedication to excellence, Somnomed has garnered a reputation for its high-quality products and undisputed expertise, making it a trusted choice for both patients and healthcare professionals.

Since its establishment, Somnomed Ltd has reached several significant milestones. The company has successfully developed and patented innovative medical devices, such as SomnoDent, which is widely recognized as a leading oral appliance therapy for obstructive sleep apnea. Somnomed Ltd has also expanded its global footprint, establishing a strong presence across major markets like the United States, Europe, and Asia-Pacific. Over the years, the company has fostered strong relationships with dental and medical professionals while continuously investing in research and development. With a commitment to improving the lives of patients suffering from sleep-related breathing disorders, Somnomed Ltd continues to drive innovation and deliver excellent treatment solutions.

Somnomed Ltd is primarily present in various countries and regions across the globe. The company has a strong presence in North America, including the United States and Canada, where it offers its innovative sleep apnea solutions. Additionally, Somnomed Ltd has established a significant foothold in Europe, catering to patients in countries such as Germany, France, Italy, and the United Kingdom. It also operates in the Asia-Pacific region, with key markets including Australia, New Zealand, and Japan. With its international reach, Somnomed Ltd continuously expands its presence to address the needs of individuals suffering from sleep-disordered breathing worldwide.

Somnomed Ltd represents values of excellence, innovation, and patient-centered care. With a strong corporate philosophy, the company is committed to improving the sleep health and quality of life for individuals suffering from sleep-related breathing disorders. Somnomed Ltd prioritizes the development and delivery of high-quality, clinically proven oral devices that provide effective treatment options for patients. By leveraging cutting-edge technology and a patient-focused approach, Somnomed Ltd aims to enhance sleep medicine and promote healthier sleep patterns worldwide.

Analysts currently set an average price target of 1.01 AUD for the Somnomed stock (median: 1.01 AUD), implying +150.6 % versus the latest price. The consensus is based on 7 analyst ratings.

Somnomed Analyst Price Targets 2026

7 analysts currently rate the Somnomed stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Somnomed to generate revenue of 121.67 M AUD and earnings per share of 0.01 AUD.

Somnomed Analyst Price Targets 2026

Converted at the current exchange rate, the Somnomed share trades at 0.25 EUR (0.41 AUD).

The Somnomed share (SOM.AX) is listed on 4 stock exchanges, including: Frankfurt (RJV.F), SIX (Zürich) (RJV.SW), ASX (SOM.AX).

SomnoMed Ltd is a leading player in the field of sleep medicine and specializes in the manufacturing and distribution of sleep medical devices. The company was founded in 2004 and is headquartered in Australia. However, it has a significant presence worldwide in Europe, North America, and the Asia-Pacific region. The business model of SomnoMed Ltd is based on the development, manufacturing, and distribution of sleep medical devices for the treatment of sleep apnea and snoring. The company offers a wide range of products, including SomnoDent® devices, a recognized non-CPAP solution for the treatment of obstructive sleep apnea. These devices work by gently increasing the lower jaw and tongue to open the airway passage and alleviate snoring and symptoms of obstructive sleep apnea. The company collaborates with a network of medical device dealers and sleep medicine professionals to sell and distribute its products. SomnoMed Ltd also has excellent relationships with insurers and healthcare providers to ensure that the treatment of sleep apnea is covered by their devices. SomnoMed Ltd offers value-added services such as training and support. In Europe, the company maintains its own production facility in Germany to meet the demand of local markets for specialized devices. SomnoMed is also committed to expanding and improving its product range through continuous research and development activities. SomnoMed Ltd also has an online presence and offers various online tools to assist customers in finding a sleep medicine professional near them or reviewing their insurance coverage. The company has also developed online training to educate sleep medicine professionals and customer service representatives involved in the care of patients using the SomnoMed product range. The different divisions of SomnoMed Ltd include the sleep medicine segment and the healthcare segment. The company's sleep medical devices are primarily intended for the treatment of sleep apnea and snoring. The aim of these devices is to improve the patient's breathing during sleep and thereby increase their quality of life. SomnoMed Ltd is also involved in the field of dental sleep medicine, and its devices are prescribed by sleep medicine professionals and dentists. The healthcare segment of SomnoMed Ltd focuses on healthcare services and also includes the manufacturing and distribution of medical products. The company offers training and support for its products to assist healthcare professionals in their application and patient care. In the coming years, the company is expected to continue its expansion of geographic reach, product development, and collaboration with physicians and sleep medicine professionals. The focus is on expanding market share in sleep medicine through the development of innovative products and the expansion of the distribution network.

The expected revenue of Somnomed is 121.67 M AUD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Somnomed is 2.14 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Somnomed is currently 40.12. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Somnomed stock.

The price-to-sales ratio (P/S) of Somnomed is currently 0.71. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Somnomed stock.

The Eulerpool Quality Score for Somnomed is 2/10.

The ISIN of Somnomed is AU000000SOM1. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Somnomed is A0B7QA. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Somnomed is SOM.AX. The ticker symbol is used to trade Somnomed shares on the stock exchange.

Somnomed paid dividends every year for the past 0 years.

Somnomed is assigned to the 'Health' sector.

The dividends of Somnomed are distributed in AUD.

All fundamentals and in-depth analysis of Somnomed

Our stock analysis for Somnomed stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Somnomed. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Somnomed Stock
Somnomed Revenue→
Somnomed Stock
Somnomed Net Income→
Somnomed Stock
Somnomed P/E→
Somnomed Stock
Somnomed P/S→
Somnomed Stock
Somnomed EBIT→
Somnomed Stock
Somnomed Dividend→
Somnomed Stock
Somnomed Directors Dealings→
Somnomed Stock
Somnomed Stocks→
Somnomed Stock
Somnomed Market capitalization→
Somnomed Stock
Somnomed Debt→
Somnomed Stock
Somnomed Liabilities→
Somnomed Stock
Somnomed Equity→
Somnomed Stock
Somnomed AAQS→
Somnomed Stock
Somnomed Employees→
Somnomed Stock
Somnomed ROE→
Somnomed Stock
Somnomed ROA→
Somnomed Stock
Somnomed ROCE→
Somnomed Stock
Somnomed News→
Somnomed Stock
Somnomed Analyst Price Targets→

Health Stocks

Sona NanotechSoligenixSonendoSolid BiosciencesSonic HealthcareSolbornSonida Senior LivingSolastoSonoma PharmaceuticalsSolasia Pharma KKSonoScape MedicalSolara Active Pharma SciencesAll Stocks A–Z →